SCHEMBL15051698

SCHEMBL15051698

CC(=O)Nc1cc(-n2cc(-c3nc[nH]n3)c(-c3ccccc3C#N)n2)c(C)cn1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.35
ABL1 P00519 2/20 0.35
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
JAK2 O60674 1/20 0.32
TYK2 P29597 1/20 0.32
POLQ O75417 1/20 0.32
LRRK2 Q5S007 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAP4K1 Q92918 2/20 0.32
PIK3C3 Q8NEB9 1/20 0.31
XDH P47989 1/20 0.31
TGFBR1 P36897 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051877 0.89 ABL1 (0.36) ABL1NPC1RAB9ATYK2SMN1; SMN2
SCHEMBL15050840 0.87 ABL1 (0.36) ABL1SMN1; SMN2PIK3C3
SCHEMBL15051573 0.86 ADORA3 (0.42) ABL1NPC1RAB9ALRRK2SMN1; SMN2
SCHEMBL15051589 0.86 NPC1 (0.32) ABL1NPC1RAB9ATYK2SMN1; SMN2
SCHEMBL15051323 0.85 PIK3CA (0.37) ABL1GSK3AGSK3BNPC1RAB9A
SCHEMBL15051606 0.83 NPC1 (0.32) ABL1NPC1RAB9ASMN1; SMN2PIK3C3
SCHEMBL15051313 0.81 ABL1 (0.40) ABL1NPC1RAB9ASMN1; SMN2PIK3C3
SCHEMBL15051295 0.80 RAB9A (0.35) ARABL1NPC1RAB9ASMN1; SMN2
SCHEMBL15051168 0.80 ABL1 (0.34) ABL1NPC1RAB9ATYK2SMN1; SMN2
SCHEMBL15072383 0.79 MAPK1 (0.36) ABL1NPC1JAK2TYK2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 AR 2888/4885ABL1 801/4885GSK3A 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.